Opinion|Videos|October 14, 2024

Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

Key Takeaways

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor and taxane treatments, highlighting the role of PSMA PET imaging in treatment sequencing and patient selection.